Bristol-Myers Squibb Co. (NYSE:BMY) currently has a daily average trading volume of 16.13M but it saw 11770374 shares traded in last market. With a market cap of 99.55B USD, the company’s current market price of $49.12 came falling about -2.33 while comparing to the previous closing price of $50.29. In past 52 weeks, the stock remained buoying in the range of price level as high as $70.93 and as low as $47.58.
Taking a look at 20-day trading activity of Bristol-Myers Squibb Co. (BMY) gives us an average price of $51.93, while its current price level is -30.75% below from 52-week high level whereas it is 3.24% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $51.16 while that of 200 days or SMA-200 reads an average of $54.97. A closer look into the stock’s movement over the week reveals that its volatility is standing at 1.68% during that period while stretching the period over a month that increases to 1.89%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 33.50 which implies that the stock is in neutral territory.
Redburn Atlantic downgraded its recommendation for the stock as a “Neutral” from “Buy” on February 06, 2024 while assigning a price target range of $77-$54. BofA Securities also issued its recommendations for the stock as it downgraded the price target for the stock in the range of between $68 and $60.
Over the week, BMY’s stock price is moving -4.44% down while it is -9.71% when we observe its performance for the past one month. Year-to-date it is -4.27% down and over the past year, the stock is showing a downside performance of -29.86%.
The latest quarterly earnings report issued by the company was for quarter ended 12/30/2023, when its quarterly earnings per share (EPS) of $1.57 beat the consensus estimate of $1.41 for the same. For BMY, analysts are forecasting an EPS-growth rate of -8.50% for current year and estimate for EPS growth in next year is 3.20%. In next quarter, company is expected to be making quarterly sales of $10.62 billion as analysts are expecting the sales for current fiscal year at $42.35 billion and seeing the company making $42.77 billion in sales next year. Moreover, analysts are in estimates of $10.54 billion for current-quarter revenue.
Currently, Bristol-Myers Squibb Co.’s total number of outstanding shares is 2.03B with 0.10% of that held by the insiders while 78.97% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at 11.87% and return on equity (ROE) at 26.53%. It has a price to earnings ratio (P/E ratio) of 12.73 while having a 6.96 of forward P/E ratio. Stock’s beta reads 0.40. Stock has a price to book (P/B) ratio of 3.37 while price to sale or P/S ratio amounts to 2.21. Its return on asset (ROA) is 8.36% on average.
